Mutant endoglycoceramidases with enhanced synthetic activity
AssigneeSeneb Biosciences, Inc.
InventorsKarl F. Johnson, Shawn Defrees, Stephen Withers, Mark Vaughan
Life of this patent
Estimating the term…
Loading patent…
AssigneeSeneb Biosciences, Inc.
InventorsKarl F. Johnson, Shawn Defrees, Stephen Withers, Mark Vaughan
Estimating the term…
The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.
A method of producing a glycolipid, the method comprising:
A method of producing monosialoganglioside 1 (GM1), the method comprising:
A method of producing a glycolipid, the method comprising:
Dependencies are inferred from the claim text.